Literature DB >> 22214333

Immunomodulatory properties of ES-62, a phosphorylcholine-containing glycoprotein secreted by Acanthocheilonema viteae.

Lamyaa Al-Riyami1, William Harnett.   

Abstract

Filarial nematodes are parasites that have the ability to persist in their hosts for extended periods of time due to the employment of various mechanisms to divert or down-regulate the host's immune responses. One of these mechanisms is the production of immunomodulatory excretory-secretory (ES) products. This review will discuss the properties of one such product, ES-62, which over the years, has been shown to interact with and modulate the activities of a variety of cells of the immune system including B and T lymphocytes, dendritic cells, macrophages and mast cells. Overall, ES-62 diverts the immune system towards an anti-inflammatory phenotype and consistent with this it has been shown to have therapeutic potential in models of inflammatory disease associated with autoimmunity and allergy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22214333     DOI: 10.2174/187153012799278893

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  17 in total

Review 1.  Looking beyond the induction of Th2 responses to explain immunomodulation by helminths.

Authors:  T B Nutman
Journal:  Parasite Immunol       Date:  2015-06       Impact factor: 2.280

2.  Novel therapeutic compound tuftsin-phosphorylcholine attenuates collagen-induced arthritis.

Authors:  T Bashi; O Shovman; M Fridkin; A Volkov; I Barshack; M Blank; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

Review 3.  Systemic impact of intestinal helminth infections.

Authors:  P K Mishra; M Palma; D Bleich; P Loke; W C Gause
Journal:  Mucosal Immunol       Date:  2014-04-16       Impact factor: 7.313

Review 4.  Effect of helminth-induced immunity on infections with microbial pathogens.

Authors:  Padmini Salgame; George S Yap; William C Gause
Journal:  Nat Immunol       Date:  2013-11       Impact factor: 25.606

Review 5.  The Secretome of Filarial Nematodes and Its Role in Host-Parasite Interactions and Pathogenicity in Onchocerciasis-Associated Epilepsy.

Authors:  An Hotterbeekx; Jolien Perneel; Melissa Krizia Vieri; Robert Colebunders; Samir Kumar-Singh
Journal:  Front Cell Infect Microbiol       Date:  2021-04-28       Impact factor: 5.293

6.  Protective effect of small molecule analogues of the Acanthocheilonema viteae secreted product ES-62 on oxazolone-induced ear inflammation.

Authors:  Lamyaa Al-Riyami; David T Rodgers; Justyna Rzepecka; Miguel A Pineda; Colin J Suckling; Margaret M Harnett; William Harnett
Journal:  Exp Parasitol       Date:  2015-03-30       Impact factor: 2.011

Review 7.  Parasitic Nematode Immunomodulatory Strategies: Recent Advances and Perspectives.

Authors:  Dustin Cooper; Ioannis Eleftherianos
Journal:  Pathogens       Date:  2016-09-14

Review 8.  Helminths and their implication in sepsis - a new branch of their immunomodulatory behaviour?

Authors:  Marc P Hübner; Laura E Layland; Achim Hoerauf
Journal:  Pathog Dis       Date:  2013-09-10       Impact factor: 3.166

9.  The role of individual protein kinase C isoforms in mouse mast cell function and their targeting by the immunomodulatory parasitic worm product, ES-62.

Authors:  Kara S Bell; Lamyaa Al-Riyami; Felicity E Lumb; Graham J Britton; Alastair W Poole; Christopher M Williams; Ursula Braun; Michael Leitges; Margaret M Harnett; William Harnett
Journal:  Immunol Lett       Date:  2015-09-03       Impact factor: 3.685

10.  Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis.

Authors:  Lamyaa Al-Riyami; Miguel A Pineda; Justyna Rzepecka; Judith K Huggan; Abedawn I Khalaf; Colin J Suckling; Fraser J Scott; David T Rodgers; Margaret M Harnett; William Harnett
Journal:  J Med Chem       Date:  2013-11-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.